Please ensure Javascript is enabled for purposes of website accessibility

Why Share of Novavax Inc Dropped 34% in January

By Brian Feroldi - Feb 6, 2016 at 8:06AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Novavax's shares couldn't sidestep the month's biotech beatdown.

What: The shares of Novavax (NVAX 2.00%), a clinical-stage biotechnology company focused on vaccines, had a January to forget, as shares shed 34% of their value during the month, according to data from S&P Capital IQ. 

The company wasn't alone in its plunge as the SPDR S&P Biotech ETF (XBI 1.19%), an ETF that invests primarily in small-cap biotechnology stocks, had an awful month, as well.

XBI Chart

So what: Despite the horrendous decline, the company only had two news items released during the month that were worthy of mention, neither of which can explain the market's reaction.

  • Novavax announced that it was raising $300 million from a convertible bond offering. Those notes mature in 2023, and if converted to shares, would do so at a price of $6.81, representing a 22.5% premium to Novavax's share price at the time of issuance.
  • The company presented at the JP Morgan Healthcare conference, where it confirmed that its RSV F vaccines trials are on schedule, and that the company expects new clinical readouts in the second half of the year.

Now what: Until Novavax can bring its vaccines to market and start to generate revenue, its stock is going to be subject to the whims of the biotech market, so it's no surprise to see its shares fall so much when the XBI takes a hit. Novavax stock also finished a very prosperous 2015, so perhaps traders were simply in profit-taking mode with the company's shares during the month as they bailed out of the biotech sector.

Regardless of its stock's short-term price movements, Novavax's future remains tied directly to the success of its RSV F vaccine, and with late-stage clinical data being reported later this year, it should be an interesting year for investors. If the data continues to look promising, then it's likely that the vaccine will be in regulators' hands by 2017. Given that the RSV virus afflicts tens of millions of patients around the world, each year it looks to hold blockbuster potential.

Investors with a high tolerance for risk might want to consider giving Novavax's discounted share price a closer look.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

SPDR Series Trust - SPDR S&P Biotech ETF Stock Quote
SPDR Series Trust - SPDR S&P Biotech ETF
$94.90 (1.19%) $1.12
Novavax, Inc. Stock Quote
Novavax, Inc.
$42.30 (2.00%) $0.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.